Super Trial

A Phase 2b, Multi-Center, Placebo-Controlled, Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy School-Age Children to Assess the Immunological Response and Safety Profile of a Single Dose BPZE1 With and Without Co-Administration of Tetanus, Diphtheria, and Acellular Pertussis (Boostrix™)

 

This is an international study enrolling 600 children/teenagers aged 6 to 17 years old and is being funded by a company called ILiAD Biotechnologies.

Development of a Vaccine against Salmonella Paratyphi A (VASP)

You are invited to take part in a study to investigate whether a novel vaccine can prevent paratyphoid fever. The study is being run by the Oxford Vaccine Group which is part of the University of Oxford and is funded by the Medical Research Council. If you are aged 18 to 55 years old, and in good health, then you may be eligible to take part in the study. We will provide reimbursement for your time, inconvenience, and travel. Participants will receive up to £2965 if they remain in the study for the entire period.

MENACWY = MEN7B-003

MenABCWY=Men7B-003 : A Phase II, randomised, partially blinded study to assess the safety, tolerability, and immunogenicity of meningococcal combined ABCWY vaccine when administered to healthy infants.

Short Title: Combining vaccines against meningitis: An infant immunisation study

Oxford Vaccine Group would like to invite your baby to participate in a study looking at a new combined Meningitis vaccine, designed to allow us to give babies protection against many different strains of meningitis using fewer injections.

COVID-19 Challenge Study (COV-CHIM 01)

What is the purpose of this study and why participate?

SARS-CoV-2 is the virus responsible for COVID-19 disease. Recent roll out of licensed vaccines is a positive step towards fighting COVID-19. However, we don’t know how long protection after COVID-19 infection and/ or vaccination lasts and why some people can get infected a second time..

POInT

The Oxford Vaccine Group is recruiting infants aged 4 – 7 months to a type 1 diabetes prevention trial. POInT (Primary Oral Insulin Trial) is recruiting infants who were screened for diabetes at birth through the INGR1D Study and have been found to be at high risk for developing diabetes.